Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04644809 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3561774 in Participants With Dyslipidemia
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT04644809 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 74 participants.
The verdict
NCT04644809, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.
Interventions
- DRUG Placebo
- DRUG LY3561774
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2022-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04644809
The ClinicalTrials.gov registry entry for NCT04644809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04644809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04644809 about?
NCT04644809 is a clinical study titled "A Study of LY3561774 in Participants With Dyslipidemia". This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also b...
What is the current status of trial NCT04644809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2020-11-30. Estimated completion is 2022-05-17.
What interventions are being tested in trial NCT04644809?
The interventions under investigation include: Placebo (DRUG), LY3561774 (DRUG).
Who is sponsoring clinical trial NCT04644809?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.